La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Sunzen Biotech Berhad Bilan de santé

Santé financière contrôle des critères 5/6

Sunzen Biotech Berhad possède un total de capitaux propres de MYR138.0M et une dette totale de MYR6.7M, ce qui porte son ratio d'endettement à 4.8%. Son actif total et son passif total sont MYR158.6M et de MYR20.6M. L'EBIT de Sunzen Biotech Berhad est MYR12.2M ce qui fait que son ratio de couverture des intérêts 45.8. Elle dispose de liquidités et de placements à court terme de MYR23.0M.

Informations clés

4.8%

Ratio d'endettement

RM 6.66m

Dette

Ratio de couverture des intérêts	45.8x
Argent liquide	RM 22.98m
Fonds propres	RM 137.98m
Total du passif	RM 20.65m
Total des actifs	RM 158.63m

Mises à jour récentes de la santé financière

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Mar 26

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Dec 10

Recent updates

Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher

Aug 06

If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity

May 25

Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking

May 24

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Apr 22

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Nov 16

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Mar 26

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Dec 10

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de SUNZEN ( MYR55.7M ) dépassent ses passifs à court terme ( MYR9.9M ).

Passif à long terme: Les actifs à court terme de SUNZEN ( MYR55.7M ) dépassent ses passifs à long terme ( MYR10.7M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: SUNZEN dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de SUNZEN est passé de 4.8% à 4.8% au cours des 5 dernières années.

Couverture de la dette: La dette de SUNZEN est bien couverte par le flux de trésorerie opérationnel ( 141.6% ).

Couverture des intérêts: Les paiements d'intérêts de SUNZEN sur sa dette sont bien couverts par l'EBIT ( 45.8 x couverture).

Sunzen Biotech Berhad Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Recent updates

Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher

Now 22% undervalued

If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity

Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Sunzen Biotech Berhad Announces Appointment of Aida Lim Binti Abdullah as Independent and Non Executive Member of Nomination Committee

Third quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 3Q 2022)

Sunzen Biotech Berhad Announces Resignation of Zeenath Begum Binti Mohamed Mastan as Joint Company Secretary

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Sunzen Biotech Berhad Announces Appointment of Lee Yew Weng as Non Independent and Non Executive Member of Remuneration Committee

Sunzen Biotech Berhad Appoints Lee Yew Weng as Non Independent and Non Executive Member of Nomination Committee

Second quarter 2023 earnings released: EPS: RM0.001 (vs RM0.001 in 2Q 2022)

Sunzen Biotech Berhad Announces the Resignation of Dr. Fong Chan Seng as Independent and Non Executive Director, Member of Remuneration Committee, Chairman of Nomination Committee

First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 1Q 2022)

Sunzen Biotech Berhad Announces Redesignation of Ching Chee Pun as Executive Chairman

Full year 2022 earnings released: EPS: RM0.005 (vs RM0.001 in FY 2021)

Third quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 3Q 2021)

Second quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 2Q 2021)

First quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 1Q 2021)

Sunzen Biotech Berhad Announces Resignation of Lim Lee Kuan as Company Secretary

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sunzen Biotech Berhad Announces the Re-Designation of Teo Yek Ming from Group Chief Executive Officer to Group Managing Director

Sunzen Biotech Berhad (KLSE:SUNZEN) completed the acquisition of Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap.

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Full year 2020 earnings released: RM0.025 loss per share (vs RM0.034 loss in FY 2019)

New 90-day high: RM0.22

Sunzen Biotech Berhad (KLSE:SUNZEN) entered into a conditional share sale agreement to acquire Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap for MYR 12.4 million.

New 90-day high: RM0.20

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Third quarter 2020 earnings released: RM0.001 loss per share

Sunzen Biotech Berhad Announces Re-Designation of Ching Chee Pun from Non-Independent Director to Executive Director

First half earnings released

New 90-day high - RM0.21

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines